CSIMarket Company Name, Ticker, Customers, else..
 
C4 Therapeutics Inc   (NASDAQ: CCCC)
 
Price: $3.7600 $0.02 0.535%
Day's High: $3.8399999141693115 Week Perf: 1.35 %
Day's Low: $ 3.66 30 Day Perf: 3.3 %
Volume (M): 2,361,956 52 Wk High: $ 5.17
Volume (M$): $ 0 52 Wk Avg: $2.93
Open: $3.72 52 Wk Low: $1.69



 Market Capitalization (Millions $) 491
 Shares Outstanding (Millions) 131
 Employees 104
 Revenues (TTM) (Millions $) 35
 Net Income (TTM) (Millions $) -101
 Cash Flow (TTM) (Millions $) -17
 Capital Exp. (TTM) (Millions $) 1

Business Description


C4 Therapeutics Inc is a biotechnology company that specializes in developing novel therapeutics based on targeted protein degradation. They aim to pioneer a new class of drugs known as Degronimid™ molecules, which selectively eliminate disease-causing proteins within the cell. By harnessing the natural protein disposal system called the ubiquitin-proteasome system, C4 Therapeutics hopes to address a wide range of diseases, including cancer and neurodegenerative disorders. Their approach has the potential to provide more effective and safer treatment options for patients.


   Company Address: 490 Arsenal Way Watertown 2472 MA
   Company Phone Number: 231-0700   Stock Exchange / Ticker: NASDAQ CCCC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AURA        2.16% 
AUTL   -4.27%    
BCAB   -45.44%    
CRDF        15.96% 
CRIS   -9.4%    
INBX   -1.82%    
• View Complete Report
   



Clinical Study

Evaluating C4 Therapeutics Cemsidomide Promising Phase 1 Developments Amidst Financial Challenges in Multiple Myelom...

Published Mon, Sep 22 2025 3:18 AM UTC

In an era where multiple myeloma therapies are rapidly evolving, C4 Therapeutics Inc. has emerged front and center with their promising investigational drug, Cemsidomide. Presented at the International Myeloma Society Annual Meeting, Phase 1 clinical trial data has highlighted the potential of Cemsidomide to achieve remarkable efficacy in a heavily pre-treated relapsed/refra...
Clinical Study

C4 Therapeutics and Betta Pharmaceuticals Launch CFT8919 Clinical Trials in Greater China

Published Wed, Nov 6 2024 12:01 PM UTC

C4 Therapeutics, a biopharmaceutical company specializing in the development of targeted protein degradation therapies, recently announced the dosing of the first patient in a clinical trial for its investigational drug CFT8919. This event marks a significant milestone not only for C4 Therapeutics but also for its partner, Betta Pharmaceuticals, as they embark on clinical ...
Clinical Study

for This C4 Therapeutics Set to Unveil Groundbreaking Cemsidomide Data at ASH Annual Meeting, Fueling Hope in ...

Published Tue, Nov 5 2024 2:00 PM UTC

Advancements in Cancer Treatment: C4 Therapeutics to Unveil Promising Data on Cemsidomide at ASH Annual Meeting The Stage is Set In the rapidly evolving landscape of cancer treatment, C4 Therapeutics (C4T) is poised to reveal groundbreaking data from their ongoing Phase 1/2 clinical trial of Cemsidomide, a pioneering drug candidate targeting multiple myeloma and non-Hodgkin...
Clinical Study

C4 Therapeutics Surpasses Milestones Unveils Promising Development Candidate and Hosts Key Webcast on New Cancer...

Published Tue, Sep 10 2024 11:00 AM UTC

Delivery of Second Development Candidate to Biogen Marks Key MilestoneWATERTOWN, Mass. November 28, 2023 C4 Therapeutics, Inc. (C4T), a cutting-edge biopharmaceutical company at the forefront of targeted protein degradation science, has announced a significant stride in its partnership with Biogen, following the successful delivery of its second development candidate. Thi...
Clinical Study

C4 Therapeutics Unveils Promising Phase 1 Clinical Data for CFT1946 at ESMO Congress 2024

Published Sun, Sep 8 2024 10:05 PM UTC

News C4 Therapeutics, a leader in the development of targeted protein degradation therapies, has announced its plans to present preliminary clinical data from the Phase 1 monotherapy trial of CFT1946 at the upcoming European Society for Medical Oncology (ESMO) Congress 2024. The announcement comes with the release of an abstract that showcases a favorable safety profile alo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 14.02
Price to Sales (Expected) -
Price to Book 1.99
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.24
Working Capital Ratio 6.43
Leverage Ratio (MRQ) 0.45
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.07 $
Revenues (TTM) 0.27 $
Cash Flow (TTM) -
Cash 2.3 $
Book Value 1.89 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 336,913
Net Income per Employee (TTM) -975,154
Receivable Turnover Ratio (TTM) 10.65
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.11

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -397.88 %
Net Margin (MRQ) -355.9 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



C4 Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.